Key takeaway
What This Development Means
The European Commission has extended the use of bis(2-ethylhexyl) phthalate (DEHP) in medical devices to 1 July 2030, postponing the original deadline of May 2025. This extension, part of Regulation EC 2023/2482, aligns with the transitional periods for medical device regulations (EU) 2017/745 and (EU) 2017/746, allowing more time for a gradual shift to DEHP-free medical devices. The extension aims to maintain public health standards and address challenges faced by companies in transitioning to DEHP-free alternatives. This regulatory change results from successful advocacy by the medical device industry, emphasising collaboration between industry and regulators.
What is the new deadline for the use of DEHP in medical devices, and what was the original deadline?
The new deadline for the use of DEHP in medical devices is 1 July 2030, extended from the original deadline of May 2025. This extension allows more time for a gradual shift to DEHP-free medical devices, aligning with the transitional periods for medical device regulations (EU) 2017/745 and (EU) 2017/746.
Why was the deadline for DEHP use in medical devices extended?
The deadline was extended to address the challenges faced by companies in replacing DEHP amidst regulatory complexities and the limited capacity of notified bodies. The extension aims to ensure a high level of protection for health services and patients without compromising current quality and safety requirements, while providing manufacturers with more time to innovate and integrate DEHP-free alternatives into their devices.
Source basis: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ%3AL_202302482
The European Commission has recently revised Regulation (EC) No 1907/2006, extending the use of bis(2-ethylhexyl) phthalate (DEHP) in medical devices. Originally, the use of DEHP was to be subject to authorisation requirements after May 2025, but the new regulation, EC 2023/2482, issued on November 13, 2023, postpones this deadline. This amendment aligns with the extended transitional periods for medical device regulations (EU) 2017/745 and (EU) 2017/746, reflecting the need for a gradual shift to DEHP-free medical devices.
Key Points Of The Amended REACH Authorisation Requirements
- Extension of the sunset date for DEHP use in medical devices to July 1, 2030.
- Latest application date for uses of DEHP in medical devices is set to January 1, 2029.
- Assurance of continued availability of medical devices during the transition to DEHP-free alternatives.
- Acknowledgment of the challenges faced by companies in replacing DEHP amidst regulatory complexities.
This regulatory change aims to maintain public health and patient safety standards while addressing the limited capacity of notified bodies and the challenges companies face in transitioning to DEHP-free alternatives. The Commission emphasises the importance of ensuring a high level of protection for health services and patients, without compromising current quality and safety requirements.
Successful Advocacy By The Medical Device Industry
The changes are the result of a positive engagement between industry and regulators on the impact of regulation on market sectors. Working together enables better regulation to protect human health and the environment.
For years, DEHP has been one of the most commonly used plasticisers in medical devices including the following applications:
- Blood bags & intravenous bags
- Nutrition pockets
- Tubing
- Catheters
- Respiratory masks
- Disposable gloves
Earlier this year, MedTech Europe welcomed the positive opinion of the REACH Committee of extending the latest application date and the sunset date to the new transition period of the sector-specific Medical Devices Regulation.
What Next?
Use of DEHP in medical devices within the European Economic Area (EEA) will necessitate authorisation post the extended sunset date. This delay offers manufacturers using DEHP an opportunity to innovate and integrate DEHP-free alternatives into their devices. Should the new deadlines not provide sufficient leeway, EEA-based manufacturers are advised to seek authorisation before the newly set application date.
Keep updated with Signal for the latest developments and expert analysis on this and other pressing medical device matters as they unfold.
Related Articles
ECHA Launches Consultation On Microplastics Reporting Under REACH
Participate in ECHA's consultation on microplastics reporting under REACH. Submit your input by 20 January 2025 to shape regulations for synthetic polymer microparticles.
EU Explores Restrictions On Harmful Chemicals 4-OPnEO And 4-NPnEO In Articles
ECHA evaluates risks of 4-OPnEO and 4-NPnEO in articles like coatings and glass, aiming for potential EU-wide restrictions to protect the environment.
4-tert-OPnEO Authorised For Use As An Emulsifier In A Silicone Oil Emulsion
This application is vital for the siliconisation of pre-filled syringes in medicinal products.
